Taysha Gene Therapies, Inc. Capital Expenditures Incurred but Not yet Paid
Taysha Gene Therapies, Inc. (TSHA) reported Capital Expenditures Incurred but Not yet Paid of $378.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-11
- Taysha Gene Therapies, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$386.00K.
- Taysha Gene Therapies, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was $388.00K.
- Taysha Gene Therapies, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $23.00K.
- Taysha Gene Therapies, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-12-31 was -$314.00K.
- Taysha Gene Therapies, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $46.00K, a 155.56% increase from fiscal 2023.
- Taysha Gene Therapies, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $18.00K, a 95.35% decline from fiscal 2022.
- Taysha Gene Therapies, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $387.00K, a 174.47% increase from fiscal 2021.
- Taysha Gene Therapies, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $141.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $378.00K 10-Q · filed 2026-08-11 | |||
| 2025-09-30 | -$386.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.00K derived: sum of 2 quarters · filed 2026-08-11 | $25.00K 10-Q · filed 2025-11-04 | -$289.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $388.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $411.00K 10-Q · filed 2026-08-11 | $97.00K derived: sum of 3 quarters · filed 2026-08-11 | $12.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $23.00K 10-Q · filed 2026-05-06 | -$291.00K derived: sum of 2 quarters · filed 2026-05-06 | -$376.00K derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$314.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$399.00K derived: sum of 2 quarters · filed 2026-03-19 | $46.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | -$85.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $360.00K 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $445.00K 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | -$405.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $18.00K 10-K · filed 2025-02-26 | ||
| 2023-09-30 | $423.00K 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $347.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $278.00K derived: sum of 2 quarters · filed 2024-03-19 | $366.00K derived: sum of 3 quarters · filed 2024-03-19 | $387.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | -$69.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $19.00K derived: sum of 2 quarters · filed 2023-11-14 | $40.00K 10-Q · filed 2023-11-14 | -$23.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $109.00K 10-Q · filed 2023-08-14 | $46.00K derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $21.00K 10-Q · filed 2023-05-11 | -$42.00K derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $141.00K 10-K · filed 2023-03-28 | ||
| 2021-09-30 | $204.00K 10-Q · filed 2022-11-08 | |||
| 2021-03-31 | $128.00K 10-Q · filed 2022-05-16 | |||
| 2020-06-30 | $90.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $90.00K 10-Q · filed 2021-08-16 | $105.00K derived: sum of 3 quarters · filed 2021-08-16 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $15.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $15.00K 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |